サンプル依頼リスト カート
  • English
  • Korean
表紙：風疹診断検査の世界市場-2023年～2030年
市場調査レポート
商品コード
1347975

風疹診断検査の世界市場-2023年～2030年

Global Rubella Diagnostic Testing Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 185 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
風疹診断検査の世界市場-2023年～2030年
出版日: 2023年09月11日
発行: DataM Intelligence
ページ情報: 英文 185 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

麻疹は非常に感染力が強いです。無防備な状態で麻疹ウイルスに暴露されると、10人中9人程度が感染します。妊娠初期の妊婦が風疹に感染すると、90％の確率で先天性風疹症候群（CRS）の赤ちゃんが生まれます。麻疹は1人がかかると12～18人に感染する可能性があり、最も感染力が強いにもかかわらずワクチンで予防可能な病気です。

麻疹に罹りやすい人（ワクチン未接種／麻疹に罹ったことがない人）の約10人中9人が発病します。先天性風疹症候群の乳児の33％は1歳までに死亡します。先天性風疹症候群を疑う妊娠前、妊娠中、妊娠後を含め、風疹免疫の評価には風疹IgG血清検査を用いるべきです。妊娠中の風疹感染は、流産（妊娠20週以内の胎児の死亡）や死産（20週以降の死亡）につながる可能性があります。

市場力学

世界の特定地域での麻疹アウトブレイクの増加

世界の一部地域では麻疹の流行が再発し、診断検査が増加しています。米国疾病予防管理センターによると、米国では2000年に麻疹の撲滅が宣言されたもの、2019年には米国の31州で1992年以来最も多い約1,300件の麻疹患者が報告されました。データによると、世界保健機関（WHO）が2023年8月初旬に発表したところによると、インドは2023年時点で57,550人と、世界のその他の地域に比べて麻疹患者数が最も多いです。イエメンは24,596人、パキスタンは10,549人です。

麻疹ワクチンは、2000年から2021年の間に世界中で5,600万人以上の命を救っています。しかし、再発のためその数は減少しています。麻疹の流行が見られる特定の地域に住む人々の病気を治療するために、診断検査が行われています。国連国際児童緊急基金（UNICEF）によると、2022年に世界のワクチン接種率は回復しました。しかし、2019年より210万人多い2,050万人の子どもたちが、救命ワクチンの接種を受けられずにいます。

2022年には、インドは93％の接種率を達成したにもかかわらず、ワクチン未接種および接種不足の子どもが160万人にのぼります。このような数の減少により、この病気は一部の地域で再発し、すぐに他の地域にも広がります。集団感染は、ワクチン接種率が最も低い地域で起こります。したがって、上記の要因が予測期間中の市場を牽引すると予想されます。

その他、検査方法の進歩、風疹アウトブレイクの再発、予防接種回数の減少などが、今後予測される期間の市場を牽引する要因のいくつかです。

妊婦における偽陽性

風疹IgM検査は、風疹が疑われる症例に限定すべきです。無症状の人のスクリーニングには推奨されません。リウマトイド因子の存在もIgMの偽陽性を引き起こす可能性があります。IgMは偽陽性の可能性があるため、風疹免疫の有無を判定するためのルーチン検査に含めるべきではありません。無症状で曝露していない妊娠中の人に対する風疹IgM検査は、偽陽性が生じる可能性があり、誤解を招く可能性があるため不適切です。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 世界の特定地域における麻疹アウトブレイクの増加
    • 抑制要因
      • 妊婦における偽陽性の検査結果
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • DMIの見解

第6章 COVID-19分析

第7章 診断テスト別

  • ラテックス凝集
  • 肝機能検査
  • 酵素免疫測定法（EIA）
  • ラジオイムノアッセイ（RIA）
  • 蛍光免疫測定法（FIA）
  • その他

第8章 年齢層別

  • 新生児
  • 10代
  • 成人

第9章 エンドユーザー別

  • 病院・診療所
  • 診断検査室
  • 外来手術センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Siemens Healthineers AG
    • 企業概要
    • 診断技術のポートフォリオと説明
    • 財務概要
    • 主な動向
  • Bio Rad Laboratories Inc.
  • Abbott Laboratories
  • BioMerieux SA
  • Thermo Fisher Scientific Inc.
  • ZEUS Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Ortho Clinical Diagnostics
  • InDevR, Inc.
  • Beckman Coulter Inc.

第13章 付録

目次
Product Code: CD2133

Overview

Measles is highly contagious. Around 9 out of 10 people who are not protected will become infected following exposure to the measles virus. A pregnant woman infected with rubella in early pregnancy has up to a 90% chance of giving birth to a baby with congenital rubella syndrome (CRS). One person with measles can infect 12-18 people, making it the most infectious yet vaccine-preventable disease.

Around 9 out of 10 susceptible people (unvaccinated/have never had measles) who are exposed to measles will get sick. 33% of infants with congenital rubella syndrome die before one year. Rubella IgG serology testing should be used for assessing rubella immunity, including before, during, and after pregnancy suspecting congenital rubella syndrome. Rubella infection during pregnancy can lead to miscarriage (loss of the fetus within 20 weeks of conception) and stillbirth (death after 20 weeks).

Market Dynamics

Increasing measles outbreaks in certain parts of the world

The Reoccurrence of measles outbreaks in some parts of the world increases diagnostic testing. According to the Centers for Disease Control and Prevention, although measles was declared eliminated in the United States in 2000, almost 1,300 cases of measles were reported in 31 states in the U.S. in 2019, the most significant number since 1992. According to data, the World Health Organization said in early August 2023, India had the highest number of measles cases compared to the rest of the world, with 57,550 cases as of 2023. Yemen with 24,596 and Pakistan with 10,549 patients.

Measles vaccines saved more than 56 million lives worldwide between 2000-2021. However, the numbers are declining due to its reoccurrence. Diagnostic testing comes into play to treat the disease in individuals living in specific regions where measles outbreaks are observed. According to the United Nations International Children's Emergency Fund (UNICEF), global vaccination coverage has recovered in 2022. However, there are still 20.5 million children missing out on lifesaving vaccines globally, 2.1 million more than in 2019.

In 2022, India accounted for 1.6 million unvaccinated and under-vaccinated children despite achieving 93 percent coverage. These reducing numbers make the reoccurrence of the disease in a few regions and immediately spread to other regions as well because the disease is highly contagious. The outbreaks happen in those areas where the vaccination is at its lowest. Hence, the above factor is expected to drive the market in the forecast period.

Some of the other factors that drive the market are advancements in testing procedures, reoccurrence of rubella outbreaks, and decreased number of vaccinations are a few factors that are expected to drive the market in the forthcoming period.

False positive test results in pregnant women

Rubella IgM testing should be limited to suspected rubella cases. It is not recommended for screening asymptomatic people. The presence of rheumatoid factor can also result in a false positive IgM. Due to the possibility of false positive results, IgM should not be included in routine testing to determine evidence of prior rubella immunity. Rubella IgM testing in asymptomatic, unexposed pregnant people is inappropriate because false positive results can occur, which can be misleading.

Segment Analysis

The global rubella diagnostic testing is segmented based on diagnostic test, age group, end user, and region.

The enzyme immunoassay (EIA) is expected to hold the largest market share during the forecast period, owing to the rising incidences of rubella and the advantages of the enzyme immunoassay (EIA) method. For instance, the enzyme immunoassay is the most used as it is relatively inexpensive, technically easy to perform, rapid, and susceptible.

EIA is used to detect rubella-specific immunoglobulin G (IgG) antibodies. IgM testing is the most commonly performed technique using commercial enzyme immunoassay (EIA) kits. The blood test detects antibodies the immune system makes to kill the rubella virus, which remains in the bloodstream for years. The EIA is also suitable for diagnosing acute infections, as a significant increase in antibody levels was detected in all paired specimens tested from patients with acute rubella infection.

In July 2021, it reported that measles and rubella are two of the most globally critical vaccine-preventable diseases (VPD), and measuring antibodies to measles and rubella viruses in samples collected from serosurveys can play an important role in estimating population immunity and guiding immunization activities and enzyme immunoassay is the most convenient method and accessible approach for detecting the rubella virus. Hence, the efficacy is elevated if ELISA kits are used. This factor is expected to drive the market in the forecast period.

Geographical Analysis

Asia Pacific is expected to hold the largest segment in the market. According to information from the Centers for Disease Control and Prevention, India has the highest number of cases between April and September 2022. Pakistan stayed in 7th position with 3635 cases, while the US had 33 cases by the end of 2022.

Due to the increased number of cases in 2022, the Indian government has launched a scheme to improve the diagnostic services related to measles disease. For instance, in July 2022, the Pradhan Mantri Surakshit Matritva Abhiyan by the Ministry of Health & Family Welfare (MoHFW), Government of India, to improve the quality and coverage of antenatal care (ANC), including diagnostics and counseling services, as part of the Reproductive Maternal Neonatal Child and Adolescent Health (RMNCH + A) strategy.

COVID-19 Impact Analysis on Rubella Diagnostic Testing Market

COVID-19 negatively impacted the global market during the outburst because to prevent further COVID-19 infection, restrictions and regulations were imposed, making it difficult for people to perform rubella diagnoses affecting the sales of the rubella diagnostic kits. Furthermore, during the pandemic, regular vaccination programs were on hold, which according to NIH estimation, put 80 million infants at risk of infection by measles, polio, and diphtheria, negatively impacting the global market.

Market Segmentation

By Diagnostic Technique

  • Latex Agglutination
  • Liver Function Tests
  • Enzyme Immunoassay (EIA)
  • Radioimmunoassay (RIA)
  • Fluorescent Immunoassay (FIA)
  • Others

By Age Group

  • Neonates
  • Teenagers
  • Adults

By End User

  • Hospitals and Clinics
  • Cancer Diagnostic Centers
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the rubella diagnostic testing market include: Siemens Healthineers AG, Bio Rad Laboratories Inc., Abbott Laboratories, BioMerieux SA, Thermo Fisher Scientific Inc., ZEUS, Scientific Inc., F. Hoffmann-La Roche Ltd, Ortho Clinical Diagnostics, InDevR, Inc., and Beckman Coulter Inc. among others.

Key Developments

  • In 2023, The Immunization Agenda 2030 Measles & Rubella Partnership (M&RP), a partnership led by the American Red Cross, United Nations Foundation, Centers for Disease Control and Prevention (CDC), Gavi, the Vaccines Alliance, the Bill and Melinda French Gates Foundation, UNICEF and WHO, to achieve the IA2030 measles and rubella specific targets.
  • In August 2022, Roche reported that the United States Food and Drug Administration (USFDA) has approved a label expansion for its Ventana MMR RxDx Panel that provides clinicians with access to a fully automated panel of mismatch repair (MMR) biomarkers tested by immunohistochemistry (IHC).
  • In 2021, The United Kingdom Health Security Agency's Immunization and Vaccine-Preventable Diseases Division launched a new rash-fever surveillance scheme. The aim is to increase the number of samples tested for measles and rubella diagnostic testing. The program was initiated by the United Kingdom government, which distributed rubella diagnostic kits for rapid rubella testing.

Why Purchase the Report?

  • To visualize the global rubella diagnostic testing segmentation based on diagnostic test, age group, end user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of rubella diagnostic testing market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global rubella diagnostic testing market report would provide approximately 61 tables, 61 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Diagnostic test
  • 3.2. Snippet by Age Group
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Measles Outbreaks in Certain Parts of the World
    • 4.1.2. Restraints
      • 4.1.2.1. False Positive Test Results in Pregnant Women
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Diagnostic test

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test
    • 7.1.2. Market Attractiveness Index, By Diagnostic Test
  • 7.2. Latex Agglutination*
    • 7.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test
    • 7.2.2. Market Attractiveness Index, By Diagnostic Test
  • 7.3. Liver Function Tests
  • 7.4. Enzyme Immunoassay (EIA)
  • 7.5. Radioimmunoassay (RIA)
  • 7.6. Fluorescent Immunoassay (FIA)
  • 7.7. Others

8. By Age Group

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 8.1.2. Market Attractiveness Index, By Age Group
  • 8.2. Neonates*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Teenagers
  • 8.4. Adults

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals and Clinics*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Diagnostic laboratories
  • 9.4. Ambulatory surgical Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic test
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic test
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic test
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic test
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic test
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Siemens Healthineers AG
    • 12.1.1. Company Overview
    • 12.1.2. Diagnostic technique Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Bio Rad Laboratories Inc.
  • 12.3. Abbott Laboratories
  • 12.4. BioMerieux SA
  • 12.5. Thermo Fisher Scientific Inc.
  • 12.6. ZEUS Scientific Inc.
  • 12.7. F. Hoffmann-La Roche Ltd
  • 12.8. Ortho Clinical Diagnostics
  • 12.9. InDevR, Inc.
  • 12.10. Beckman Coulter Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us